KIAA1549-BRAF/BaF3
CBP73384
詢(xún) 價(jià)
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. Introduction | |
| Cell Line Name： | KIAA1549-BRAF/BaF3 |
| Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Application: | Anti-proliferation assay and PD assay |
| Freeze Medium: | 90% FBS+10% DMSO |
| Complete Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin |
| Mycoplasma Status: | Negative |
| II. Background | |
| KIAA1549-BRAF is the most frequently identified genetic mutation in sporadic pilocytic astrocytoma (PA), creating a fusion BRAF (f-BRAF) protein with increased BRAF activity.It is generated by a focal tandem duplication at 7q34 and acts as an oncogene by driving the mitogen-activated protein kinase (MAPK) pathway.The fusion was almost exclusively found in pilocytic astrocytomas, diffuse leptomeningeal glioneuronal tumours and high-grade astrocytomas with piloid features. | |
| III. Representative Data | |
|
1. WB of KIAA1549-BRAF/BaF3
|
|
|
2. Anti-proliferation assay |
|
 |
|
|
Figure 2. CTG Proliferation Assay of KIAA1549/BRAF BaF3 Cells (C1). |
|
